Rationale Surrounding Luspatercept as Potential First-Line Treatment Option for Patients With MDS

Dr Jamie L. Koprivnikar discusses the rationale surrounding luspatercept as a potential first-line treatment option for patients with myelodysplastic syndrome, and if it would have been an appropriate therapy for the patient in the presented case study.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Case Presentation: A 72-Year-Old Woman with Single Lineage Dysplasia Myelodysplastic Syndrome (MDS)

EP: 2.Approaches to Diagnosis and Risk Assessment for Patients With MDS

EP: 3.Differences in Treatment Approaches for Low-Risk and High-Risk MDS

EP: 4.Current Unmet Needs for Patients With Low-Risk MDS in the Frontline Setting

EP: 5.Luspatercept as a Treatment Option in MDS

EP: 6.Efficacy and Safety of Luspatercept in MDS: Key Data from the COMMANDS Trial

Now Viewing

EP: 7.Rationale Surrounding Luspatercept as Potential First-Line Treatment Option for Patients With MDS

EP: 8.Future Perspectives and Unmet Needs for Patients With MDS

Recent Videos

Treatment Implementation and Long-Term Considerations in BPDCN

Academic Perspectives on the Evolving Treatment Landscape in MPNs

Adverse Events Monitoring and Management in BPDCN Treatment

Academic Perspectives on Treatment Decisions for BPDCN

Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches

Advances in MPN Management: Insights From MANIFEST-2 and Beyond

Ongoing studies of Ra-223–based combinations

Academic Perspectives on Systemic Therapy for Advanced uHCC

Ongoing studies of Ra- 223–based combinations

Protecting bone health for patients receiving Ra-223 + ARPI combination